Valneva SE: Difference between revisions

Revision as of 11:58, 9 February 2025

French biotechnology company

Valneva SE

Type	Public
Key people	Thomas Lingelbach (CEO)
Industry	Biotechnology
Products	Vaccines
Website	[valneva.com Official website]

Valneva SE is a French biotechnology company that specializes in the development and commercialization of vaccines for infectious diseases. The company was formed in 2013 through the merger of Vivalis SA and Intercell AG. Valneva is headquartered in Saint-Herblain, France.

History

Valneva was established in 2013 following the merger of two European biotechnology companies, Vivalis SA from France and Intercell AG from Austria. The merger aimed to create a leading company in the field of vaccines, leveraging the strengths of both companies in research and development.

Products

Valneva focuses on developing vaccines for infectious diseases with significant unmet medical needs. Some of the key products in Valneva's portfolio include:

IXIARO: A vaccine for the prevention of Japanese encephalitis, a disease prevalent in Asia.
DUKORAL: An oral vaccine for the prevention of cholera and traveler's diarrhea caused by Escherichia coli.
VLA2001: A vaccine candidate for COVID-19, which is based on an inactivated virus platform.

Research and Development

Valneva invests heavily in research and development to expand its vaccine portfolio. The company collaborates with various organizations and governments to advance its vaccine candidates through clinical trials. Valneva's R&D efforts are focused on diseases such as Lyme disease, chikungunya, and Zika virus.

Collaborations and Partnerships

Valneva has established several partnerships to enhance its research capabilities and market reach. Notable collaborations include agreements with the U.S. Department of Defense for the development of a chikungunya vaccine and with Pfizer for the development of a Lyme disease vaccine.

Financial Performance

Valneva is publicly traded on the Euronext stock exchange. The company has experienced growth in revenue due to the successful commercialization of its vaccines and strategic partnerships.

Related pages

References

@@ Line 1: / Line 1: @@
-'''Valneva SE''' is a [[biotechnology]] and [[pharmaceutical company]] that specializes in the development, manufacturing, and commercialization of [[vaccines]] for infectious diseases with major public health implications. The company, headquartered in [[Saint-Herblain]], [[France]], has a significant presence in the global vaccine market, focusing on travel and endemic vaccines.
+{{Use dmy dates|date=October 2023}}
+{{Short description|French biotechnology company}}
+{{Infobox company
+ | name = Valneva SE
+ | logo = Valneva_logo.svg
+ | type = Public
+ | industry = Biotechnology
+ | founded = 2013
+ | headquarters = Saint-Herblain, France
+ | key_people = Thomas Lingelbach (CEO)
+ | products = Vaccines
+ | website = [https://www.valneva.com/ valneva.com]
+}}
+'''Valneva SE''' is a French [[biotechnology]] company that specializes in the development and commercialization of [[vaccines]] for infectious diseases. The company was formed in 2013 through the merger of Vivalis SA and Intercell AG. Valneva is headquartered in [[Saint-Herblain]], [[France]].
 ==History==
-Valneva SE was formed through the merger of [[Intercell AG]], an Austrian biotech company, and [[Vivalis SA]], a French biopharmaceutical company, in 2013. This strategic merger combined Intercell's expertise in vaccine development with Vivalis's innovative cell line manufacturing technologies, positioning Valneva as a leader in the vaccine industry.
+Valneva was established in 2013 following the merger of two European biotechnology companies, Vivalis SA from France and Intercell AG from Austria. The merger aimed to create a leading company in the field of vaccines, leveraging the strengths of both companies in research and development.
-==Products and Research==
+==Products==
-Valneva's product portfolio includes vaccines for [[Japanese encephalitis]] (IXIARO®/JESPECT®), [[Cholera]] (DUKORAL®), and [[Lyme disease]], among others. The company is also known for its development of a single-shot [[chikungunya]] virus vaccine, which has reached Phase 3 clinical trials, showcasing Valneva's commitment to addressing global health challenges.
+Valneva focuses on developing vaccines for infectious diseases with significant unmet medical needs. Some of the key products in Valneva's portfolio include:
-One of Valneva's most notable achievements is its development of a candidate vaccine for [[COVID-19]], leveraging its established platform and expertise in vaccine research and development. This effort highlights the company's agility in responding to emergent global health crises.
+* '''IXIARO''': A vaccine for the prevention of [[Japanese encephalitis]], a disease prevalent in Asia.
+* '''DUKORAL''': An oral vaccine for the prevention of [[cholera]] and [[traveler's diarrhea]] caused by ''[[Escherichia coli]]''.
+* '''VLA2001''': A vaccine candidate for [[COVID-19]], which is based on an inactivated virus platform.
-==Operations==
+==Research and Development==
-Valneva operates several state-of-the-art manufacturing facilities across Europe, including in [[Scotland]], [[Sweden]], and [[Austria]], which are pivotal in the production of its vaccines. These facilities adhere to the highest standards of quality and safety, ensuring the global distribution of vaccines to combat infectious diseases.
+Valneva invests heavily in [[research and development]] to expand its vaccine portfolio. The company collaborates with various organizations and governments to advance its vaccine candidates through clinical trials. Valneva's R&D efforts are focused on diseases such as [[Lyme disease]], [[chikungunya]], and [[Zika virus]].
 ==Collaborations and Partnerships==
-Valneva has established numerous partnerships with governments, global health organizations, and other pharmaceutical companies to expand its vaccine distribution and development capabilities. These collaborations are crucial for advancing vaccine research and making vaccines more accessible worldwide.
+Valneva has established several partnerships to enhance its research capabilities and market reach. Notable collaborations include agreements with the [[U.S. Department of Defense]] for the development of a chikungunya vaccine and with [[Pfizer]] for the development of a Lyme disease vaccine.
 ==Financial Performance==
-As a publicly traded company on the Euronext Paris and the Nasdaq Stock Market, Valneva has demonstrated strong financial performance, with steady revenue growth driven by vaccine sales and development contracts. The company's financial health is critical for sustaining its research and development efforts and expanding its vaccine portfolio.
+Valneva is publicly traded on the [[Euronext]] stock exchange. The company has experienced growth in revenue due to the successful commercialization of its vaccines and strategic partnerships.
-==Challenges and Future Directions==
+==Related pages==
-Valneva faces challenges common to the pharmaceutical industry, including regulatory hurdles, competition, and the complexities of vaccine development. However, the company's focus on niche markets, such as travel vaccines and diseases with unmet medical needs, positions it well for future growth. Valneva continues to invest in research and development to expand its vaccine portfolio, with a strong pipeline of vaccine candidates addressing various infectious diseases.
+* [[Biotechnology]]
+* [[Vaccine]]
+* [[Pharmaceutical industry]]
-[[Category:Pharmaceutical companies of France]]
+==References==
-[[Category:Biotechnology companies]]
+{{Reflist}}
+[[Category:Biotechnology companies of France]]
 [[Category:Vaccine producers]]
+[[Category:Companies established in 2013]]
-{{pharma-stub}}
+[[Category:Companies listed on Euronext Paris]]